Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 47, Issue 3

Issues

Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods

Marie Monge / Guillaume Jean / Jean-Louis Bacri / Vincent Lemaitre / Eric Masy / Dominique Joly
  • 6Service de Néphrologie, Hôpital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris (APHP), Université Paris-Descartes, Paris, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jean-Claude Souberbielle
  • 7Laboratoire d'Explorations Fonctionnelles and INSERM Unit 845, Hôpital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris (APHP), Université Paris-Descartes, Paris, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2009-02-09 | DOI: https://doi.org/10.1515/CCLM.2009.068

Abstract

Background: The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend maintaining serum parathyroid hormone (PTH) concentration between 150 and 300 pg/mL in patients with chronic kidney disease (CKD) stage 5. However, a marked inter-method variability in PTH measurement has been reported recently. The aim of this study was to evaluate whether harmonization of the results measured with two commercial kits known to produce significantly different serum PTH concentrations could be reasonably achieved by a simple procedure.

Methods: The study comprised a total of 216 hemodialyzed patients in whom blood was collected immediately before a dialysis session. The patients were from three dialysis centers, which defined three groups (119, 34, and 63 patients for groups 1, 2, and 3, respectively). PTH was measured by two automated assays, the Elecsys (Roche Diagnostics) and Architect (Abbott Diagnostics) assays, in three different laboratories and with different lots of reagents. We arbitrarily chose the Roche assay as the reference method, because several studies had previously shown that the concentrations measured with this assay were very close to the Allegro assay used in the studies that defined the K/DOQI thresholds. Data are median (interquartile range).

Results: The median PTH concentrations were higher (p<0.001) in the Architect assay [238 (140–434) pg/mL] when compared to the Elecsys assay [182 (109–338) pg/mL]. Bland-Altman plots in the three groups showed a similar proportional bias between both kits. The Architect PTH/Elecsys PTH ratios were similar in the three groups [1.30 (1.25–1.35), 1.30 (1.19–1.39), and 1.31 (1.25–1.35)], and the ratio was 1.30 (1.25–1.35) in the cohort (pooling the three groups). In the whole population, 53 patients (24.5%) were classified differently by the two kits according to the K/DOQI cut-off values. We divided the Architect values by 1.3 to obtain “corrected” values. These corrected Architect values were not different to the measured Elecsys values, and the Bland-Altman plot comparing the Elecsys and the corrected Artchitect values did not show any systematic proportional bias. Only six patients (2.8%) were still classified differently by the Elecsys and the corrected Architect concentrations.

Conclusions: We propose to divide the PTH values measured with the Architect PTH assay by 1.3 so that the corrected values are almost identical to those measured with the Elecsys assay.

Clin Chem Lab Med 2009;47:362–6.

Keywords: assay standardization; hemodialysis; immunoassay; Kidney Disease Outcomes Quality Initiative (K/DOQI); parathyroid hormone

About the article

Corresponding author: Jean-Claude Souberbielle, Hôpital Necker-Enfants Malades, Laboratoire d'Explorations Fonctionnelles, 161 rue de Sèvres, 75743 Paris Cedex 15, France


Received: 2008-09-15

Accepted: 2008-12-05

Published Online: 2009-02-09

Published in Print: 2009-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 47, Issue 3, Pages 362–366, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.068.

Export Citation

©2009 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Helen Eddington, Julie E Hudson, Robert L Oliver, William D Fraser, Alastair J Hutchison, and Philip A Kalra
Annals of Clinical Biochemistry, 2014, Volume 51, Number 2, Page 228
[2]
Gabriele Donati, Giuseppe Cianciolo, Irene Capelli, Olga Baraldi, Camilla Gambaretto, Valentina Demelas, Antonio Marchetti, and Gaetano La Manna
Artificial Organs, 2016, Volume 40, Number 10, Page 1013
[3]
T.G. Valderhaug, J.K. Hertel, N. Nordstrand, P.O. Dale, D. Hofsø, and J. Hjelmesæth
Diabetology & Metabolic Syndrome, 2015, Volume 7, Number 1
[4]
Jean-Claude Souberbielle, Etienne Cavalier, and Guillaume Jean
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 6
[5]
Jean-Claude P. Souberbielle, Hubert Roth, and Denis P. Fouque
Kidney International, 2010, Volume 77, Number 2, Page 93

Comments (0)

Please log in or register to comment.
Log in